
    
      This protocol is to collect blood and PBMC specimens from individuals with active of past
      COVID-19 infection. The first blood draw will be done at the first study visit and if
      eligible, the second collection will be done via leukapheresis at the second visit. The
      leukapheresis procedures will follow the facility's standard operating procedures and
      protocol requirements for leukapheresis.

      Donors will be males or females between and including the ages of 18 years and 60 years.
      Volunteers will provide written informed consent and meet all inclusion and exclusion
      criteria. Each participant can be in the study for up to 180 days (6 months).

      The study will be conducted in accordance with human research for the purposes of obtaining
      clinical specimens for research. There is no endpoint for this study, however, data collected
      from this study will include, but not be limited to, gender, demographics, medical history,
      clinical laboratory values, and volume of the blood collected. The data will be summarized in
      future studies reporting results from a future clinical trial under FDA IND.
    
  